Explorer
Advertisement
DCGI allows Phase II-III clinical trial of Covaxin on 2 to 18-years-old
The Drugs Controller General of India (DCGI) has accorded permission to conduct the Phase II-III clinical trial of Covaxin in the age group of two to 18-years-old to its manufacturer Bharat Biotech Ltd, Union Health Ministry said on Thursday.
"The trial will be conducted in 525 healthy volunteers," said the Ministry.
In the trial, the Ministry said, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.
In a latest update on the vaccination front, the gap between two doses of the Covishield Covid-19 vaccine can be increased to 12-16 weeks, as per the government panel suggestions.
India
Single-Member Panel To Probe Allegations Against Trainee IAS Officer Puja Khedkar | ABP News
'Headline Grabbing Exercise By Non-Biological PM': Jairam Ramesh As BJP Announces 'Samvidhaan Hatya Diwas' | ABP News
Delhi Flood: Repair Work Underway On Munak Canal Barrage | ABP News
Madhya Pradesh: In Singrauli, People Built 2500 New Houses On The Highway For Compensation | ABP News
Delhi: CM Arvind Kejriwal To Be In Tihar Jail Over CBI Case | ABP News
View More
Advertisement
Advertisement
Advertisement
Top Headlines
Maharashtra
Election 2024
India
India
Advertisement
Trending News
Abhishek ChakrabortyChief Copy Editor
Opinion